Aimee O Hersh1, Spencer Cope2, John F Bohnsack1, Akbar Shakoor3, Albert T Vitale3. 1. a Division of Rheumatology, Department of Pediatrics , University of Utah School of Medicine , Salt Lake City , Utah , USA. 2. b University of Texas San Antonio, Center for Health Sciences , San Antonio , Texas , USA. 3. c Department of Ophthalmology , John A. Moran Eye Center, University of Utah School of Medicine , Salt Lake City , Utah , USA.
Abstract
PURPOSE: To describe the treatment and outcomes of a cohort of pediatric intermediate uveitis (IU) patients, with a particular focus on the use of immunomodulatory therapy (IMT). METHODS: The disease course, treatment, and outcomes of 39 pediatric IU patients treated in the Uveitis Clinic at the University of Utah from 1999 to 2012 were reviewed, retrospectively. RESULTS: Mean age at presentation was 7.7 years (SD 3.1). In total, 95% had bilateral involvement. Out of 77 total eyes involved, the most frequent disease complications were ocular hypertension (0.71 events per person year, PPY), cataracts (events PPY = 0.39), and cystoid macular edema (events PPY = 0.33). A total of 20 patients received IMT; 19/20 were tapered off systemic corticosteroids without a uveitis recurrence; 75% of eyes had inactive disease at final follow-up (mean 37 months). CONCLUSIONS: The use of IMT, including biologic therapies, may effectively manage disease inflammation and reduce steroid dosages in pediatric IU patients.
PURPOSE: To describe the treatment and outcomes of a cohort of pediatric intermediate uveitis (IU) patients, with a particular focus on the use of immunomodulatory therapy (IMT). METHODS: The disease course, treatment, and outcomes of 39 pediatric IU patients treated in the Uveitis Clinic at the University of Utah from 1999 to 2012 were reviewed, retrospectively. RESULTS: Mean age at presentation was 7.7 years (SD 3.1). In total, 95% had bilateral involvement. Out of 77 total eyes involved, the most frequent disease complications were ocular hypertension (0.71 events per person year, PPY), cataracts (events PPY = 0.39), and cystoid macular edema (events PPY = 0.33). A total of 20 patients received IMT; 19/20 were tapered off systemic corticosteroids without a uveitis recurrence; 75% of eyes had inactive disease at final follow-up (mean 37 months). CONCLUSIONS: The use of IMT, including biologic therapies, may effectively manage disease inflammation and reduce steroid dosages in pediatric IU patients.
Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258
Authors: Lourdes Arellanes-García; Patricia Navarro-López; Luz Elena Concha-Del Río; Jose Antonio Unzueta-Medina Journal: Int Ophthalmol Clin Date: 2008
Authors: Asta Baranauskaite; Helena Raffayová; N V Kungurov; Anna Kubanova; Algirdas Venalis; Laszlo Helmle; Shankar Srinivasan; Evgeny Nasonov; Nathan Vastesaeger Journal: Ann Rheum Dis Date: 2011-10-12 Impact factor: 19.103